In patients with type 2 diabetes, adiponectin increased in both the exenatide-plus-insulin and insulin-only groups, without an intervention-specific association.
In plain wordsAdiponectin increased in both diabetes treatment groups, without a specific link to exenatide.
- Peptide
- Exenatide (exendin-4)
- Outcome
- IncreaseAdiponectin increase in both groups
- Study
n = 110
- Outcome group
- Inflammation markers · Metabolic and weight
Measurements
- Adiponectin change
- 24.2%
- groups B and C
- Adiponectin change interquartile range
- 14.8 to 53.2%
- groups B and C
Source sentences
In the subgroup intervention trial, adiponectin was significantly raised in both groups B and C (t-Student for paired samples, p=0.001) by Δ=+24.2% (interquartile range 14.8-53.2%).
2 context sentences(design, population, supporting numbers)
This elevation was not associated with the type of intervention but with weight loss, glycemic control and reduction of C-reactive protein (one-way ANCOVA).
A subgroup of patients (n=110), after assessed for eligibility criteria, was blindly randomized to receive either 6-month exenatide supplementation on glargine insulin (group B) or intense, self-regulated, insulin therapy alone (group C).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).